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Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease primarily involving inflammation of the joints. Although
the management of the disease has advanced significantly in the past three decades, there is still no cure for RA. The aim of this
study was to determine the therapeutic efficacy of 𝛿-tocotrienol, in the rat model of collagen-induced arthritis (CIA). Arthritis was
induced by intradermal injection of collagen type II emulsified in complete Freund’s adjuvant. CIA rats were orally treated with
𝛿-tocotrienol (10mg/kg) or glucosamine hydrochloride (300mg/kg) from day 25 to 50. Efficacy was assessed based on the ability to
reduce paw edema, histopathological changes, suppression of collagen-specific T-cells, and a reduction in C-reactive protein (CRP)
levels. It was established that 𝛿-tocotrienol had the most significant impact in lowering paw edema when compared to glucosamine
treatment. Paw edema changes correlated well with histopathological analysis where there was a significant reversal of changes in
groups treated with 𝛿-tocotrienol. The results suggest that 𝛿-tocotrienol is efficient in amelioration of collagen-induced arthritis.
Vitamin E delta-tocotrienol may be of therapeutic value against rheumatoid arthritis.
1. Introduction
Rheumatoid arthritis is a chronic inflammatory and destruc-
tive arthropathy.The worldwide occurrence of RA is about 1–
1.5% of the population and it does not discriminate between
age and ethnicity [1]. The precise aetiology of RA remains
unknown. It has been established however that this disease
is strongly linked with major histocompatibility complex
(MHC) class II antigens, suggesting a genetic predisposition
[2]. The pathogenesis of RA is associated with the activation
of both cellular and humoral immune responses to an
autoantigen [2, 3]. The activation of such responses leads to a
potentiation of various proinflammatory cytokines (TNF-𝛼,
IL-1𝛽, etc.), cascading into a vicious cycle of antigenic stim-
ulation, inflammation, and joint destruction [4]. Currently,
only symptomatic treatment of RA is available. Treatment for
RA is unsatisfactory, as it consists of drugs with serious side
effects and does not correct the underlying causes of arthritis.
Therefore, there is a dire need for a safer and equally, if not
more, efficient treatment option which is able to attack the
root of the disease itself.
Nutraceuticals are loosely defined as “functional foods”
and food products that provide medicinal or health benefits
[5]. With a reported market value of US$ 75 billion, this
industry is becoming progressively popular, partly due to the
public’s perception that “natural is better” [6]. Joining a long
list of nutraceuticals are the tocotrienols, a constituent of
vitamin E found in palm oil as a phytonutrient [7]. Vitamin
E is a collective name for a complex mixture of homologues.
The two main homologues of vitamin E are the tocopherols
(T) and tocotrienols (T3). Each homology is subsequently
composed of four isomers, 𝛼, 𝛽, 𝛾, and 𝛿. Tocomonoenol,
found in small quantities in palm oil and marine organisms,
forms the third homologue of vitamin E. Two isomers of
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tocomonoenol have been described to date with not much
known about either [8]. Gaining substantial momentum in
the past decade, tocotrienol research has led to the discovery
of many of its important properties. Ranging from anticancer
[9] to neuroprotective qualities [10], it is clear that tocotrienol
use in various disease states is warranted. One such disease
is rheumatoid arthritis (RA). The anti-inflammatory effects
of tocotrienols have been less studied. Only recently, it has
come to light that these isomers of vitamin Emight bear some
consequences on eradicating chronic inflammatory diseases
such as arthritis, atherosclerosis, and coeliac disease to name
a few. The aim of the present study is to assess the efficacy of
𝛿-tocotrienol supplementation as a therapeutic agent in the
collagen-induced rat model of arthritis.
2. Materials and Methods
Female Dark Agouti (DA) rats, 6–10 weeks old (150–200 g),
were obtained from the Institute of Medical Research (IMR),
Malaysia. Rats were maintained in individually ventilated
cages (4 per cage) in theAnimalHolding Facility (AHF) at the
International Medical University (IMU) after their arrival.
Food and water were available to the animals ad libitum.
The AHF environment was climate-controlled with a 12-
hour day and 12-hour night cycles.The International Medical
University’s joint committee for research and ethics approved
all experimental procedures of this study. Delta-tocotrienol
was a kind gift from Davos Life Sciences (Singapore). Colla-
gen from chicken sternal cartilage type II, complete Freund’s
adjuvant (CFA), glucosamine hydrochloride, and acetic acid
99.8% were obtained from Sigma (Sigma Aldrich, USA).
Rats were divided randomly into four experimental
groups (𝑛 = 6 in each group), control, arthritis alone, arthritis
with 𝛿-tocotrienol treated, and arthritis with glucosamine
treated. Collagen from chicken sternal cartilage (5mg) was
reconstituted in 5mL of 0.1M cold acetic acid. The collagen
was left to solubilise overnight at 4∘C. Once the solution had
become clear, complete Freund’s adjuvant (CFA) at a ratio of
1 : 1 was added to the preparation of collagen.Themixture was
then transferred to a handheld homogeniser and emulsified
for approximately 20minutes. For collagen-induced arthritis,
the rats were briefly anesthetized and approximately 0.2–
0.4mL of the collagen-CFA emulsion was injected intrader-
mally at the base of the tail at day 0. For the treatment group
10mg/kg bodyweight of𝛿-tocotrienolwas administered daily
using feeding needles from day 25 to day 50. The amount
administered was at a concentration of 10mg/kg rat based on
the weight of the rat at day 25. Treatment was administered
as oral supplementation daily through oral gavage from day
25 to day 50. Arthritis with glucosamine group received
300mg/kg body weight of glucosamine hydrochloride daily
through oral gavage from day 25 to day 50.
The body weight of the animals was measured at five
intervals. Rats were monitored daily for general appearance
and behavior. The severity of arthritis was quantified by
measuring the rat paw thickness using a digital vernier caliper
at five-day intervals. Paw measurements were taken at each
limb at four different joint positions. Twenty-four hours
after the last day of the experiment, rats were anesthetized
and blood sample was collected by cardiac puncture. Joint
samples were also collected for histopathology. Spleen was
removed and placed in a Petri dish containing approximately
5mL RPMI media. Cells were immediately harvested and
stored on ice. The plasma C-reactive protein (CRP) levels
were quantified using the Millipore rat C-reactive protein
ELISA kit.
2.1. Collagen Stimulation of Splenic Leukocytes. For collagen
stimulation of splenic leukocytes, the tubes containing the
cell suspension were centrifuged at 800 rpm for 5 minutes
after which the supernatant was discarded. 1mL of complete
RPMI media and 3mL of RBC lysis buffer were added to the
pelleted cells. The tube was inverted gently several times for
30 seconds to ensure mixture of the buffer and the pellet.
Then, the tubes were centrifuged again at 800 rpm for 5
minutes and the supernatant was discarded. The pellet was
then resuspended in 2mL of RPMI media. For the counting
of cells, 100𝜇L of the cell suspension is diluted with 900 𝜇L
of complete RPMI medium. Then, 20 𝜇L of this suspension
was transferred into a microcentrifuge tube and 20𝜇L of
trypan-blue dye was added to the cells. The trypan-blue dye
stains dead cells and this will help to eliminate the counting
of these cells. The suspension was transferred onto a glass
haemocytometer and viewed under the microscope. Viable
leukocytes were counted. The cell number was adjusted to
5 × 10
6 cells/mL using the culture medium. About 200𝜇L
of this cell suspension was added in triplicate to the wells
of a sterile 96-well flat-bottomed plate in the presence of
5 𝜇g/mL collagen. The plate was left to incubate for 72 hours
in a humidified CO2 incubator at 37∘C. Cell proliferation was
determined using the MTT assay.
2.2. Histopathology. After being fixed in 10% formalin for one
week, the joint tissues were transferred to a tube containing
a decalcifying agent. Following decalcification, the tissue was
processed using an automated tissue processor and embed-
ding station. Blocks were sectioned at 3-4 𝜇m thickness and
slides were prepared and stained (H&E).
2.3. Statistical Analysis. All data were analyzed using SPSS
version 18 (SPSS Inc., Chicago, IL, USA). One-way analysis
of variance (ANOVA) was used to detect differences among
the experimental groups. For detecting differences between
any two groups in a multiple group comparison, Tukey’s test
was used to evaluate paw oedema data and readings obtained
from the ELISA. For all tests, a 𝑃 value of less than 0.05 was
considered to be significant.
3. Results
3.1. The Severity of Arthritis. Arthritic animals began to have
restrictions in movement at around day 20 where signs of
arthritis began to develop. Some animals had developed a
limp andmoved around dragging their paws. Eating patterns,
however, remained normal as denoted by a linear weight gain.
As treatment progressed fromday 25 to day 50, themobility of
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Figure 1: Effect of delta-tocotrienol on hind-paw edema. Hind-paws on day 50 of the experiment. Normal rats (a) from control group showed
no signs of joint inflammation. Gross morphology of the hind-paws of arthritis rats showed maximal swelling and redness over joints (b).
Treatment with tocotrienol and glucosamine reduced the severity of paw inflammation ((c) and (d)).
the rats supplemented with either glucosamine or tocotrienol
improved and almost all the rats in these groups regained
ability to move around freely. Apart from the arthritis that
affected the joints of these animals, there were no other gross
changes observed (Figure 1).
3.2. Paw Edema. Paw edema was quantified by measuring
paw size using a digital caliper from day 25 to 50. Arthritic
animals began to show signs of arthritis between days 15 and
20. A total of 16 joints were measured for changes in swelling.
Prior to induction, all rats showed no signs of arthritis or
any paw deformities (Figure 1(a)). Signs of arthritis observed
included swelling and redness over the joints, development
of a limp, and tenderness to touch. In all rats, more than
two joints were involved on each limb. As paw edema was
most prominent on the hind-paws; only the joints in the
hind-paws were assessed analytically using Tukey’s post hoc
test. Joints showed a significant (𝑃 < 0.05) decrease in paw
edema for all treated groups when compared to the untreated
group (Table 1 and Figures 1(c) and 1(d)). Comparison
between tocotrienol and glucosamine revealed a significantly
higher (𝑃 < 0.05) effect of 𝛿-tocotrienol in reducing paw
edema (Table 1). In the supplement-treated groups, swelling
and redness over the joints reduced markedly and the rats
regained their mobility. There was no recurrence of oedema
in the joints and no additional joints became involved during
this period (Table 1 and Figure 1).
3.3. Body Weight. Body weight of each rat was measured
and recorded every five days from day 25 to 50. Although
the starting weight for each group differed slightly, there
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Figure 2: Effect of delta-tocotrienol on body weight changes in
arthritis rats. Data are expressed as mean ± standard error. ∗𝑃 <
0.05: arthritis versus other groups.
was a noticeable upward trend for all groups (𝑃 < 0.05).
The body weight of the animals ranged between 123.1 g and
138.9 g on day 35 and between 132.4 g and 156.8 g on day
50. The average body weight of all the animals rose between
10 and 12 g throughout the treatment period. The arthritis
alone group had the highest ending weight. There was a
significant increase in the body weight in this group after day
40 when compared with the other three groups (𝑃 < 0.05).
The arthritic rats supplemented with 𝛿-tocotrienol showed
significantly lower weight compared to the arthritis alone and
control groups (𝑃 < 0.05) (Figure 2).
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Table 1: Effect of delta-tocotrienol on percentage changes in paw edema in arthritis rats.
Days Left hind limb joint Right hind limb joint
Arthritis Arthritis + tocotrienol Arthritis + glucosamine Arthritis Arthritis + tocotrienol Arthritis + glucosamine
Day 25 100 ± 2.2 100 ± 1.2 100 ± 1.5 100 ± 1.3 100 ± 2.4 100 ± 2.5
Day 30 98.37 ± 3.4 94.74 ± 2.8∗ 92.35 ± 1.2 94.87 ± 4.1 92.05 ± 3.7 94.76 ± 3.2
Day 35 95.93 ± 3.7 88.05 ± 3.8∗ 90.91 ± 4.1∗ 92.71 ± 2.1 89.94 ± 2.8∗ 91.45 ± 2.4
Day 40 92.05 ± 4.8 84.35 ± 5.4∗ 88.75 ± 3.4∗ 90.19 ± 3.7 85.45 ± 2.9∗ 88.91 ± 1.1∗
Day 45 88.42 ± 4.9 80.75 ± 4.3∗⧫ 87.41 ± 2.8 88.99 ± 3.9 82.41 ± 4.1∗⧫ 84.65 ± 2.4∗
Day 50 87.24 ± 2.8 75.35 ± 2.7∗⧫ 82.15 ± 3.8∗ 87.31 ± 2.8 78.94 ± 2.1∗⧫ 79.43 ± 2.8∗
Data are expressed as mean ± standard error of six rats per group. ∗𝑃 < 0.05: arthritis versus other groups; ⧫𝑃 < 0.05: arthritis with tocotrienol versus arthritis
with glucosamine groups.
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Figure 3: Histopathological analysis of joint morphology (H&E-200x). (a) Photomicrograph of arthritis group, showing synovial fibrosis
(black arrow) and inflammatory infiltrate forming a pannus (red circle), (b) photomicrograph of arthritis + delta-tocotrienol, showing
a significant reduction in synovial hyperplasia and inflammation (black arrow) and healthy joint space (black double arrow head), (c)
photomicrograph of arthritis with glucosamine group, showing angiogenesis in the form of proliferating blood vessels (blue circle) and
surrounding synovial healing scar tissue (black double arrow head), and (d) photomicrograph of control group, showing healthy normal
joint space (double arrow head) with no inflammation or hyperplasia.
3.4. Histopathology. Histological sections were examined by
light microscopy after H&E staining. All rats in the various
arthritic groups showed significant changes in joint structure
with varying degrees of arthritis changes. Changes observed
included inflammation, cellular inflammation, joint space
narrowing, synovial hyperplasia, erosion, and fibrosis. The
joints of normal animals showed normal architecture with
no swelling of the joint space. There was adequate gap
and the articulating surfaces were lined by a healthy lining
of cartilage, beneath which was the bony trabeculae. The
synovium of these rats appeared healthy and there was no
evidence of oedema or inflammation (Figure 3(a)).
Maximum degenerative changes were observed in the
arthritis alone rats, where a feature of early and late-stage
inflammation such as widening of joint space during early
stages of the disease was observed. Severe congestion sur-
rounding the joint space had resulted in oedema, dilation
of blood vessels, and narrowing of the joint space later on.
The surface surrounding the joint space showed erosion and
degeneration (Figure 3(b)). Extensive synovial hyperplasia
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Figure 4: Proliferation of collagen-stimulated splenocytes from
arthritic rats supplemented with delta-tocotrienol and glucosamine.
Data are expressed as mean ± standard error. ∗𝑃 < 0.05: arthritis
versus other groups; ⧫𝑃 < 0.05: arthritis with tocotrienol versus
arthritis with glucosamine groups.
was also noted with increased cellular infiltration composed
primarily of inflammatory cells (lymphocytes and plasma
cells). Areas of granulomatous inflammation known as pan-
nus formed in several areas with increasing fibrosis. The
tocotrienol supplemented rats showed less severe changes
when compared to arthritis. Inflammation was scarce with
a marked reduction in edema and congestion. Only scatters
of inflammatory cells were observed, suggesting that only
moderate inflammation was present. There were few focal
areas of fibrosis present, indicating healing of the joint.
Vascular dilation was still present accompanied by moder-
ate synovial hyperplasia. Areas of active inflammation and
healing were also noted (Figure 3(c)). The joints of the rats
in the glucosamine-treated group also showed a significant
reduction in swelling. Microscopically, the orientation of
joint space was predominantly healthy and morphological
changes were minimal. There were focal areas of mild edema
and scattered inflammatory cells, amidst healthy synovial
tissue.The subsynovial regions showed good vasculature and
areas of fibrosis, signifying that the process of healthy healing
was taking place (Figure 3(d)).
3.5. Collagen-Induced Proliferation of Splenocytes. Spleno-
cytes from the arthritic rats showed maximum cell viability
when these cells were cocultured with 5𝜇g/mL collagen for
24, 48, and 72 hours. At 72 hours, cell viability was at its peak
with 85% compared with 59% for 24 hours and 62% for 48
hours. As the concentration of collagen increased, however, it
was found that the viability of cells decreased to as low as 9%.
Once the optimum concentration of collagen and incubation
time were determined, this data (not shown) was used to
determine the proliferation of splenocytes from the control
and experimental rats. Proliferation of collagen-stimulated
lymphocytes was quantified using theMTT assay.The results
showed that the proliferation of collagen-stimulated spleno-
cytes was reduced in animals that were supplemented with
glucosamine and 𝛿-tocotrienol (𝑃 < 0.05) (Figure 4).
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Figure 5: Effect of delta-tocotrienol on C-reactive protein concen-
tration. Data are expressed as mean ± standard error of six rats per
group. ∗𝑃 < 0.05: arthritis versus other groups; ⧫𝑃 < 0.05: arthritis
with tocotrienol versus arthritis with glucosamine groups.
3.6. C-Reactive Protein (CRP). Plasma levels of C-reactive
protein (CRP)were determined by using a commercial ELISA
kit using the protocol recommended by the manufacturer
(Millipore, USA). The arthritic group showed significantly
(𝑃 < 0.05) elevated levels of CRP compared to the control
group. There was a significant decrease in the CRP in the 𝛿-
tocotrienol and glucosamine-treated group (𝑃 > 0.05) when
compared to the arthritis alone group (Figure 5).
4. Discussion
This study aimed to assess the therapeutic efficacies of 𝛿-
tocotrienol. In this study, several parameters which enable the
elucidation of these potential benefits were investigated for
these purposes.
Six joints of the hind-paws were assessed for changes
in paw oedema. Only the hind-paws were chosen as they
were the most significantly affected and literature has shown
that this is a feature in collagen-induced arthritis [11]. In
four out of the six joints assessed, tocotrienol had the most
significant reduction in paw oedema when compared to all
other groups. It is clear that tocotrienol treatment had a
considerable impact on reducing paw edema.
Body weight of rats in all groups showed a linear increase
with no unusual changes. There were no significant differ-
ences noted between the experimental groups. This was an
important marker in showing that the animals were not
in distress during the experimental period. There was a
significant increase in the body weight in arthritis group after
day 40 when compared with the other three groups. This
increased weight could be due to water retention caused by
edema in these animals. Most studies on CIA show rapid
weight loss in rats during the period after induction of
arthritis, which gradually increased with remission of the
disease [12]. This was however not seen in this study.
Collagen-induced arthritis established in DA rats was
a reliable model, with a 100% incidence of arthritis. There
was consistent development of full-blown arthritis in at least
one of the hind-paws with the distal interphalangeal joint
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being involved. No rats were severely disabled to warrant
early sacrifice. Arthritis developed acutely in rats, with
joint changes occurring much more rapidly than in human
RA. This allowed for a more detailed observation of joint
changes before and after treatment. The CIA is associated
with unwanted features such as variable incidence, severity,
and intergroup inconsistency [13] which were controlled by
maintaining appropriate environmental conditions.
Macroscopically, all rats induced with arthritis showed
similar signs and arthritis had peaked by day 25. Classical
signs of CIA were observed, including symmetrical joint
involvement typically involving the hind-paws, swelling, and
erythema over the joints [14–16]. By the end of treatment
period (day 50), treated groups showed an amelioration in
signs and improved mobility of the joints. Histopathological
changes correlated with macroscopic observations, including
changes in paw oedema. Hallmarks of the CIA were noted
and were present in varying degrees amongst the different
groups. Untreated (arthritis only) rats showed maximum
degenerative changes. Suppression of disease activity was
seen in treated groups with the greatest changes in the 𝛿-
tocotrienol group.
Previous studies using animal models of arthritis showed
that anti-inflammatory effects were attained through the
inhibition of inflammatory mediators [17]. Tocotrienols have
been described to inhibit these mediators, primarily TNF-𝛼
and IL-1𝛽 [17–20], which could possibly correlate with the
attenuation histopathological changes found in these groups.
The antioxidant qualities of tocotrienols are also a key in
modulating joint injury by preventing free radical induced
damage. Tocotrienols are known to possess a higher free
radical quenching ability [21, 22]. Suppression of disease
activity with 𝛿-tocotrienols could be due to the fact that 𝛿-
tocotrienol is known to lower TNF-𝛼, IL-1𝛽, and nitric oxide
levels [18, 19]. Glucosamine is a known potent antioxidant
and has been used in osteoarthritis because of its ability to
reduce joint damage [23].This is consistent with our findings
in which glucosamine exhibited disease attenuation property
in arthritis rats.
Splenocyte proliferation was performed to determine
whether treatment with 𝛿-tocotrienol is associated with a
protection against cell-mediated immunity. Proliferation of
collagen-specific T-cells (CII-T) was assessed by the MTT
assay. Firstly, conditions in which proliferation was maximal
had to be established to determine accurate quantification
of these cells. Therefore, optimisation on the concentration
of collagen needed to stimulate appropriate amounts of CII-
T was carried out in this study. Although the procedure
for T-cell assay is well established, there seemed to be
conflicting information in the literature as to the optimum
concentration of collagen [24–27]. The results showed that,
at a concentration of 5 𝜇g/mL with an incubation time of 72
hours, proliferation was at its maximum. Collagen toxicity
towards cells increased at concentrations greater than this.
This was the case for both the normal and the arthritic
rats. It has been established that T-cell infiltration is directly
correlated with the severity of arthritis [26]. The assumption
that increased amounts of T-cells in the synovium occur as
a result of clonal expansion to specific antigens has been
explored previously [28]. In the case of CIA, the autoanti-
gen is known to be collagen type II [26]. Therefore, it is
safe to assume that high levels of CII-T cells indicate an
increased disease severity. It has been reported that when
introduced into the dermis, collagen type II is immediately
captured by antigen presenting cells (APCs). This results in
the activation and expansion of CII-T cells, initiating joint
damage [5]. Therefore, by quantifying levels of CII-T cells,
therapeutic benefits of 𝛿-tocotrienol and glucosamine were
assessed and compared. Using the set conditions, it was
found that both 𝛿-tocotrienol and glucosamine exhibited
the significant suppression of CII-T cells when compared
to the untreated groups. Both of these exhibited values
close to those of the normal nonarthritic rat. In comparison
with each other, 𝛿-tocotrienol exhibited a higher suppressive
power than glucosamine. As such, our observation that 𝛿-
tocotrienol reduced CII-T-cell proliferation may indicate a
mode of protection offered by this isomer of vitamin E against
inflammatory arthritis.
It is unclear however by which exact mechanism 𝛿-
tocotrienol was able to suppress the clonal expansion of CII-
T cells. We hypothesise that it could be through one of two
mechanisms: (i) direct suppression of the CII-T cells or (ii)
upregulation of T-regulatory (Treg) cells. Direct suppression
could arise from blocking the interaction between T-cells and
APCs or prevention of T-cell infiltration into the synovium
[28]. Treg cells have been proposed over recent years to
inhibit the initiation or downregulate immune reactions
in inflammation [29]. Studies have shown Treg cells to
prevent proliferation and cytokine production of antigenic
T-cells, thereby controlling inflammatory responses [28].
To determine which of these constitutes the underlying
mechanism, further study needs to be done. A limitation of
these findings is that it does not demonstrate a suppression
of CII-T cells over time due to tocotrienol treatment. Thus,
significant conclusions cannot be made that the tocotrienols
offer protection against RA by reducing the number of T cells.
Biomarkers of inflammation have proven to be useful
in the evaluation of disease progression and response to
therapeutic intervention in a number of systemic inflamma-
tory disorders, including RA. One such marker is C-reactive
protein (CRP). An acute phase protein, CRP, is produced
in the liver under conditions of systemic inflammation. It
is reported to be a very useful marker of inflammation as
its half life does not alter in health and disease states and it
directly correlates with the intensity of pathological processes
[12]. In clinically active human rheumatoid arthritis, levels
of CRP are found to be increased [30]. This is translated
across to animal models of rheumatoid arthritis where a
similar process is observed [12]. One study demonstrated
that high CRP levels are associated with incidence of total
joint replacement in patients with arthritis and lower levels
of CRP correspond to sustained suppression of the disease
[12]. CRP levels have also been shown to be good markers
for inflammation, bone degradation, and clinical well-being
of patients with rheumatoid arthritis [12]. Studies have also
shown that plasma CRP does not tend to rise substantially
in response to inflammation in rats [31]. Plasma CRP level
decreased significantly with 𝛿-tocotrienol and glucosamine
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treatment in this study. The 𝛿-tocotrienol and glucosamine
groups still had significantly lower levels of CRP by the
end of the experimental cycle compared to arthritis alone
group [12, 19, 30]. Production in CRP is activated by synovial
macrophages and fibroblasts mostly via a number of inflam-
matory cytokines including TNF-𝛼, IL-1, and especially IL-
6 [32]. These cytokines are similarly produced in abundance
in RA; thus it can be said that lowered levels of CRP with
tocotrienol treatment signify decreased cytokine production
and consequently decreased disease activity.
5. Conclusions
In conclusion, this study has demonstrated that oral sup-
plementation of 𝛿-tocotrienol potently attenuates the devel-
opment of progressive joint destruction in rats with CIA.
This effect is due, in part, to their ability to inhibit T-
cell proliferation, reverse histopathological changes, and
inhibit production of proinflammatory cytokines. The prop-
erties exhibited by 𝛿-tocotrienol showed promising outcomes
against collagen-induced arthritis in this study. Therefore,
there is clear evidence to suggest the potential benefits for
this tocotrienol to be used as therapeutic agent in rheumatoid
arthritis. Furthermore, insight into the possible mechanisms
of this drug and disease should be uncovered to unleash a
whole new realm of therapeutic possibilities.
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